The endocannabinoid system and rimonabant: A new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - Or inverse agonism - As potential obesity treatment and other therapeutic use

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 3, 2007, Pages 209-231

  Xie, S ^a   Furjanic, M A ^a   Ferrara, J J ^a   McAndrew, N R ^a   Ardino, E L ^a   Ngondara, A ^a   Bernstein, Y ^a   Thomas, K J ^a   Kim, E ^a   Walker, J M ^a   Nagar, S ^a   Ward, S J ^a   Raffa, R B ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Cannabinoid; CB1 receptor; Obesity; Rimonabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CLARITHROMYCIN; CYTOCHROME P450 3A4; DEXFENFLURAMINE; DRONABINOL; ENDOCANNABINOID; FENFLURAMINE; ITRACONAZOLE; KETOCONAZOLE; METHAMPHETAMINE; NEFAZODONE; OLEAMIDE; PHENDIMETRAZINE; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; RIMONABANT; RITONAVIR; SIBUTRAMINE; TELITHROMYCIN; TETRAHYDROLIPSTATIN; VIRODHAMINE;

ADIPOSE TISSUE; ALZHEIMER DISEASE; ANXIETY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BILIOPANCREATIC BYPASS; BINDING AFFINITY; BLOOD BRAIN BARRIER; BODY WEIGHT; CALORIC INTAKE; CHEMICAL STRUCTURE; CLINICAL TRIAL; DEPRESSION; DIET THERAPY; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DUODENUM; EXERCISE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GASTRIC BANDING; GENETIC SUSCEPTIBILITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LAPAROSCOPIC SURGERY; LIVER DISEASE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SCHIZOPHRENIA; SHOCK; STOMACH BYPASS; STROKE; SYNAPTIC MEMBRANE; TREATMENT OUTCOME; UNITED STATES; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; ENDOCANNABINOIDS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 34247898951     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00817.x     Document Type: Review

References (163)

1. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27, 73 100.
2. Devane WA, Hanus L, Breuer A et al 1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946 1949.
3. Mechoulam R, Ben-Shabat S, Hanus L et al 1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50, 83 90.
4. Sugiura T, Kondo S, Sukagawa A et al 1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215, 89 97.
5. Fowler CJ (2004) Oleamide: a member of the endocannabinoid family? British Journal of Pharmacology, 141, 195 196.
6. Matias I, Bisogno T, Di Marzo V (2006) Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. International Journal of Obesity, 30 (Suppl. 1 S7 S12.
7. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58, 389 462.
8. Hanus L, Abu-Lafi S, Fride E et al 2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 98, 3662 3665.
9. Porter AC, Sauer JM, Knierman MD et al 2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics, 301, 1020 1024.
10. Dougalis A, Lees G, Ganellin CR (2004) The sleep lipid oleamide may represent an endogenous anticonvulsant: an in vitro comparative study in the 4-aminopyridine rat brain-slice model. Neuropharmacology, 46, 541 554.
11. Varma N, Carlson GC, Ledent C, Alger BE (2001) Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. Journal of Neuroscience, 21, RC188.
12. Kim J, Isokawa M, Ledent C, Alger BE (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. Journal of Neuroscience, 22, 10182 10191.
13. Witting A, Walter L, Wacker J, Moller T, Stella N (2004) P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proceedings of the National Academy of Sciences of the United States of America, 101, 3214 3219.
14. Di S, Boudaba C, Popescu IR et al 2005) Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. Journal of Physiology, 569, 751 760.
15. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG (2005) Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology, 146, 4292 4301.
16. Alger BE (2002) Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Progress in Neurobiology, 68, 247 286.
17. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science, 296, 678 682.
18. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews, 83, 1017 1066.
19. Petitet F, Donlan M, Michel A (2006) GPR55 as a new cannabinoid receptor: still a long way to prove it. Chemical Biology & Drug Design, 67, 252 253.
20. Shire D, Carillon C, Kaghad M et al 1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. Journal of Biological Chemistry, 270, 3726 3731.
21. Ryberg E, Vu HK, Larsson N et al 2005) Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Letters, 579, 259 264.
22. Lynn AB, Herkenham M (1993) Localization of cannabinoid receptors and nonsaturable high-density cannabinois binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. Journal of Pharmacology and Experimental Therapeutics, 268, 1612 1623.
23. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America, 87, 1932 1936.
24. Pertwee RG (2003) Inverse agonism at cannabinoid receptors. International Congress Series, 1249, 75 86.
25. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL (1998) Overweight and obesity in the United States: prevalence and trends, 1960-1994. International Journal of Obesity and Related Metabolic Disorders, 22, 39 47.
26. Peter JV, Khan MA 2005) Obesity. In : DiPiro JT, et al. ed. Pharmacotherapy: a pathophysiologic approach, 6th edn. New York, NY : McGraw-Hill, 2660 2665.
27. Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP (1997) Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994). Obesity Research, 5, 542 548.
28. Mark DH (2005) Deaths attributable to obesity. Journal of the American Medical Association, 293, 1918 1919.
29. Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proceedings of the Nutrition Society, 60, 329 339.
30. Clement K, Ferre P (2003) Genetics and the pathophysiology of obesity. Pediatric Research, 53, 721 725.
31. Spiegelman BM, Flier JS (2001) Obesity and the regulation of energy balance. Cell, 104, 531 543.
32. Barsh GS, Farooqi IS, O'Rahilly S (2000) Genetics of body-weight regulation. Nature, 404, 644 651.
33. Kendrick ML, Dakin GF (2006) Surgical approaches to obesity. Mayo Clinic Proceedings, 81, S18 S24.
34. Palamara KL, Mogul HR, Peterson SJ, Frishman WH (2006) Obesity: new perspectives and pharmacotherapies. Cardiology in Review, 14, 238 258.
35. Ioannides-Demos LL, Proietto J, McNeil JJ (2005) Pharmacotherapy for obesity. Drugs, 65, 1391 1418.
36. Birch EA (1889) The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. Lancet, 1, 625.
37. Donovan M (1845) On the physical and medicinal qualities of Indian hemp (Cannabis indica). Dublin Journal of Medical Science, 26, 368 402.
38. Touw M (1981) The religious and medicinal uses of Cannabis in China, India and Tibet. Journal of Psychoactive Drugs, 13, 23 34.
39. Osei-Hyiaman D, DePetrillo M, Pacher P et al 2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation, 115, 1298 1305.
40. Berry EM, Mechoulam R (2002) Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacology & Therapeutics, 95, 185 190.
41. Rinaldi-Carmona M, Barth F, Heaulme M et al 1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters, 350, 240 244.
42. Rinaldi-Carmona M, Barth F, Heaulme M et al 1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sciences, 56, 1941 1947.
43. Rinaldi-Carmona M, Calandra B, Shire D et al 1996) Characterization of two cloned human CB1 cannabinoid receptor isoforms. Journal of Pharmacology and Experimental Therapeutics, 278, 871 878.
44. White R, Hiley CR (1998) The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. British Journal of Pharmacology, 125, 689 696.
45. Tzavara ET, Davis RJ, Perry KW et al 2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology, 138, 544 553.
46. Pavon FJ, Bilbao A, Hernandez-Folgado L et al 2006) Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology, 51, 358 366.
47. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003) Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology, 167, 103 111.
48. Gardner A, Mallet PE (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. European Journal of Pharmacology, 530, 103 106.
49. Carai MA, Colombo G, Maccioni P, Gessa GL (2006) Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Reviews, 12, 91 99.
50. Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136, 550 557.
51. Milano WC, Wild KD, Hui YZ, Hubbell CL, Reid LD (1988) PCP, THC, ethanol, and morphine and consumption of palatable solutions. Pharmacology, Biochemistry and Behavior, 31, 893 897.
52. Solinas M, Goldberg SR (2005) Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology, 30, 2035 2045.
53. Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology, 143, 315 317.
54. Cota D, Marsicano G, Tschop M et al 2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation, 112, 423 431.
55. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C (2003) Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. Journal of Neurochemistry, 84, 698 704.
56. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International Journal of Obesity and Related Metabolic Disorders, 28, 640 648.
57. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology, 63, 908 914.
58. Carai MA, Colombo G, Gessa GL (2005) Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sciences, 77, 2339 2350.
59. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sciences, 63, PL113 PL117.
60. Poirier B, Bidouard JP, Cadrouvele C et al 2005) The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes, Obesity & Metabolism, 7, 65 72.
61. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 284, R345 R353.
62. Jbilo O, Ravinet-Trillou C, Arnone M et al 2005) The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal, 19, 1567 1569.
63. Hildebrandt AL, Kelly-Sullivan DM, Black SC (2003) Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology, 462, 125 132.
64. Liu YL, Connoley IP, Wilson CA, Stock MJ (2005) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International Journal of Obesity, 29, 183 187.
65. Ward SJ, Dykstra LA (2005) The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behavioural Pharmacology, 16, 381 388.
66. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology, 132, 104 106.
67. Simiand J, Keane M, Keane PE, Soubrie P (1998) SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioural Pharmacology, 9, 179 181.
68. Gessa GL, Orru A, Lai P et al 2006) Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology, 185, 248 254.
69. McLaughlin PJ, Winston K, Swezey L et al 2003) The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behavioural Pharmacology, 14, 583 588.
70. Verty AN, McGregor IS, Mallet PE (2004) Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neuroscience Letters, 354, 217 220.
71. Breivogel CS, Childers SR (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiology of Disease, 5, 417 431.
72. Pontieri FE, Tanda G, Di Chiara G (1995) Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the ''shell" as compared with the ''core" of the rat nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America, 92, 12304 12308.
73. Martel P, Fantino M (1996) Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacology, Biochemistry and Behavior, 53, 221 226.
74. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science, 276, 2048 2050.
75. Hajnal A, Norgren R (2001) Accumbens dopamine mechanisms in sucrose intake. Brain Research, 904, 76 84.
76. Gomez R, Navarro M, Ferrer B et al 2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience, 22, 9612 9617.
77. Croci T, Manara L, Aureggi G et al 1998) In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. British Journal of Pharmacology, 125, 1393 1395.
78. Brown MS, Goldstein JL (1998) Sterol regulatory element binding proteins (SREBPs): controllers of lipid synthesis and cellular uptake. Nutrition Reviews, 56, S1 S3 discussion S54 S75.
79. Dooley KA, Bennett MK, Osborne TF (1999) A critical role for cAMP response element-binding protein (CREB) as a co-activator in sterol-regulated transcription of 3-hydroxy-3-methylglutaryl coenzyme A synthase promoter. Journal of Biological Chemistry, 274, 5285 5291.
80. Vallett SM, Sanchez HB, Rosenfeld JM, Osborne TF (1996) A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3- methylglutaryl coenzyme A reductase gene. Journal of Biological Chemistry, 271, 12247 12253.
81. Tontonoz P, Kim JB, Graves RA, Spiegelman BM (1993) ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Molecular and Cellular Biology, 13, 4753 4759.
82. Williams CM, Kirkham TC (2002) Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacology, Biochemistry and Behavior, 71, 341 348.
83. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG (1976) Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology, 49, 79 84.
84. Jamshidi N, Taylor DA (2001) Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology, 134, 1151 1154.
85. Di Marzo V, Goparaju SK, Wang L et al 2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410, 822 825.
86. Stanley BG, Leibowitz SF (1985) Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proceedings of the National Academy of Sciences of the United States of America, 82, 3940 3943.
87. van der Lely AJ, Tschop M, Heiman ML, Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocrine Reviews, 25, 426 457.
88. Tucci SA, Rogers EK, Korbonits M, Kirkham TC (2004) The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. British Journal of Pharmacology, 143, 520 523.
89. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P (2003) Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. Journal of Biological Chemistry, 278, 23731 23737.
90. Harris GC, Wimmer M, Aston-Jones G (2005) A role for lateral hypothalamic orexin neurons in reward seeking. Nature, 437, 556 559.
91. Elmquist JK, Elias CF, Saper CB (1999) From lesions to leptin: hypothalamic control of food intake and body weight. Neuron, 22, 221 232.
92. Verty AN, McFarlane JR, McGregor IS, Mallet PE (2004) Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology, 145, 3224 3231.
93. Gardner EL, Vorel SR (1998) Cannabinoid transmission and reward-related events. Neurobiology of Disease, 5, 502 533.
94. Hernandez L, Hoebel BG (1988) Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sciences, 42, 1705 1712.
95. Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience, 109, 451 460.
96. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G (2002) Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Research, 952, 232 238.
97. Verty AN, McGregor IS, Mallet PE (2004) The dopamine receptor antagonist SCH 23390 attenuates feeding induced by Delta9-tetrahydrocannabinol. Brain Research, 1020, 188 195.
98. Bakshi VP, Kelley AE (1993) Feeding induced by opioid stimulation of the ventral striatum: role of opiate receptor subtypes. Journal of Pharmacology and Experimental Therapeutics, 265, 1253 1260.
99. Kirkham TC, Williams CM (2001) Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology, 153, 267 270.
100. Gallate JE, McGregor IS (1999) The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716. Psychopharmacology, 142, 302 308.
101. Rowland NE, Mukherjee M, Robertson K (2001) Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology, 159, 111 116.
102. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365, 1389 1397.
103. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of the American Medical Association, 295, 761 775.
104. Goldstein DJ (1992) Beneficial health effects of modest weight loss. International Journal of Obesity and Related Metabolic Disorders, 16, 397 415.
105. Van Gaal LF, Wauters MA, De Leeuw IH (1997) The beneficial effects of modest weight loss on cardiovascular risk factors. International Journal of Obesity and Related Metabolic Disorders, 21 (Suppl. 1 S5 S9.
106. Després JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine, 353, 2121 2134.
107. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet, 368, 1660 1672.
108. Makriyannis A, Mechoulam R, Piomelli D (2005) Therapeutic opportunities through modulation of the endoccabinoid system. Neuropharmacology, 48, 1068 1071.
109. Beardsley PM, Dance ME, Balster RL, Munzar P (2002) Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys. European Journal of Pharmacology, 435, 209 216.
110. Beardsley PM, Martin BR (2000) Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal. European Journal of Pharmacology, 387, 47 53.
111. Beardsley PM, Thomas BF (2005) Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behavioural Pharmacology, 16, 275 296.
112. Mailleux P, Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. Journal of Neurochemistry, 61, 1705 1712.
113. Romero J, Berrendero F, Perez-Rosado A et al 2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sciences, 66, 485 494.
114. Gubellini P, Picconi B, Bari M et al 2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. Journal of Neuroscience, 22, 6900 6907.
115. Centonze D, Gubellini P, Rossi S et al 2005) Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience, 133, 831 840.
116. Fernandez-Espejo E, Caraballo I, de Fonseca FR, El Banoua F, Ferrer B, Flores JA, Galan-Rodriguez B (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiology of Disease, 18, 591 601.
117. Gonzalez S, Scorticati C, Garcia-Arencibia M, de Miguel R, Ramos JA, Fernandez-Ruiz J (2006) Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Research, 1073-1074, 209 219.
118. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernandez-Ruiz JJ (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. European Journal of Neuroscience, 14, 1827 1832.
119. Mesnage V, Houeto JL, Bonnet AM et al 2004) Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clinical Neuropharmacology, 27, 108 110.
120. Walter L, Stella N (2004) Cannabinoids and neuroinflammation. British Journal of Pharmacology, 141, 775 785.
121. Mazzola C, Micale V, Drago F (2003) Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. European Journal of Pharmacology, 477, 219 225.
122. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. Journal of Neuroscience, 23, 11136 11141.
123. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience, 25, 1904 1913.
124. Maldonado R, Valverda O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends in Neuroscience, 29, 225 232.
125. Pistis M, Ferraro L, Pira L et al 2002) Δ9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Research, 948, 155 158.
126. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proceedings of the National Academy of Sciences of the United States of America, 100, 1393 1398.
127. Naassila M, Pierrefiche O, Ledent C, Daoust M (2004) Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology, 46, 243 253.
128. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND (2005) Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behavioural Brain Research, 164, 206 213.
129. Rice OV, Gordon N, Gifford AN (2002) Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Research, 945, 135 138.
130. De Vries TJ, Shaham Y, Homberg JR et al 2001) A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine, 7, 1151 1154.
131. De Vries TJ, Schoffelmeer AN (2005) Cannabinoid CB1 receptors control conditioned drug seeking. Trends in Pharmacological Sciences, 26, 420 426.
132. Cohen C, Perrault G, Griebel G, Soubrie P (2005) Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology, 30, 145 155.
133. Thaker GK, Carpenter WT Jr. (2001) Advances in schizophrenia. Nature Medicine, 7, 667 671.
134. Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nature Reviews. Neuroscience, 6, 312 324.
135. Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacology, Biochemistry and Behavior, 56, 803 807.
136. Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research, 172, 556 560.
137. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. European Journal of Neuroscience, 16, 1395 1398.
138. Navarro M, Hernandez E, Munoz RM et al 1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport, 8, 491 496.
139. Arevalo C, de Miguel R, Hernandez-Tristan R (2001) Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology, Biochemistry and Behavior, 70, 123 131.
140. Bilkei-Gorzo A, Racz I, Valverde O, Otto M, Michel K, Sastre M, Zimmer A (2005) Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proceedings of the National Academy of Sciences of the United States of America, 102, 15670 15675.
141. Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG (2005) A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends in Pharmacological Sciences, 26, 609 617.
142. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH (2004) Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? Journal of Neurochemistry, 88, 1159 1167.
143. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ (2004) Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience, 129, 743 750.
144. Awumey EM, Howlett AC, Diz DI (2005) Is there a role for anandamide in cardiovascular regulation? Insights from studies of endocannabinoid metabolism. American Journal of Physiology. Heart and Circulatory Physiology, 289, H520 H521.
145. Lagneux C, Lamontagne D (2001) Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. British Journal of Pharmacology, 132, 793 796.
146. Di Filippo C, Rossi F, Rossi S, D'Amico M (2004) Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology, 75, 453 459.
147. Roth MD (2005) Pharmacology: marijuana and your heart. Nature, 434, 708 709.
148. Steffens S, Veillard NR, Arnaud C et al 2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 434, 782 786.
149. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature, 390, 518 521.
150. Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB Journal, 12, 1035 1044.
151. Sarker KP, Obara S, Nakata M, Kitajima I, Maruyama I (2000) Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Letters, 472, 39 44.
152. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. Journal of Pharmacology and Experimental Therapeutics, 270, 219 227.
153. Wang Y, Liu Y, Ito Y et al 2001) Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Analytical Biochemistry, 294, 73 82.
154. Motobe T, Hashiguchi T, Uchimura T, Yamakuchi M, Taniguchi N, Komiya S, Maruyama I (2004) Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome. Shock, 21, 8 12.
155. Gardiner SM, March JE, Kemp PA, Bennett T (2005) Involvement of CB1-receptors and beta-adrenoceptors in the regional hemodynamic responses to lipopolysaccharide infusion in conscious rats. American Journal of Physiology. Heart and Circulatory Physiology, 288, H2280 H2288.
156. Kadoi Y, Goto F (2006) Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine. Journal of Anesthesia, 20, 284 289.
157. Batkai S, Jarai Z, Wagner JA et al 2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Medicine, 7, 827 832.
158. Ros J, Claria J, To-Figueras J et al 2002) Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology, 122, 85 93.
159. Curioni C, Andre C (2006) Rimonabant for overweight or obesity. Cochrane Collaboration, 4, CD006162.
160. Tuthill A, Slawik H, O'Rahilly S, Finer N (2006) Psychiatric co-morbidities in patients attending specialist obesity services in the UK. QJM, 99, 317 325.
161. Pi-Sunyer FX (2006) In reply (letter to the editor). Journal of the American Medical Association, 296, 650 651.
162. Shearman LP, Rosko KM, Fleischer R et al 2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behavioural Pharmacology, 14, 573 582.
163. Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological Psychiatry, 57, 261 267.